Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 16 May 2025

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

in Cancer Molecular Targets and Therapeutics

Ying Jin
Ping Sun
Peng Chen
Yuqiang Xu
Guangmao Mu
Zhengxia Zha
Simin Wu
Meixia Fu
Hao Jiang
Sheng Huang

Frontiers in Oncology

doi 10.3389/fonc.2025.1533059

279 views

Correction

Accepted on 15 May 2025

Corrigendum: MiR-21 and let-7 cooperation in the regulation of lung cancer

in Cancer Molecular Targets and Therapeutics

Jinquan Bai
Zhenzhou Shi
Shuting Wang
Hong Pan
Tong Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1602462

Perspective

Published on 15 May 2025

Bringing value to cancer research

in Cancer Molecular Targets and Therapeutics

Casey J. Allen
Horn M. Danea
Fabrice Smieliauskas
Stephen Edge
Rachel A. Greenup

Frontiers in Oncology

doi 10.3389/fonc.2025.1580575

203 views

Review

Published on 15 May 2025

Circulating tumor DNA laboratory processes and clinical applications in nasopharyngeal carcinoma

in Cancer Molecular Targets and Therapeutics

Ziman Wu
Haiyan Yang
Xinying Li
Xiang Ji
Chan Mo
Zhou Zheng
Yafei Xu
Dan Xiong

Frontiers in Oncology

doi 10.3389/fonc.2025.1520733

190 views

Review

Published on 14 May 2025

Role of exosomes in castration-resistant prostate cancer

in Cancer Molecular Targets and Therapeutics

Yuan Cao
Jianjun Wang
Huiwen Luo
Yaodong Wang
Xianfu Cai
Tiansheng Zhang
Yougang Liao
Decai Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1498733

320 views

Original Research

Accepted on 13 May 2025

Metabolic profiling of glioblastoma and identification of G0S2 as a metabolic target

in Cancer Molecular Targets and Therapeutics

Jianlei Kang
Yujie Xu
Qitai Zhao
Ying Wang
Zhenyan He
Xin Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1572040

Original Research

Published on 13 May 2025

Pan-cancer analysis reveals TRA16 as a master regulator of human carcinogenesis

in Cancer Molecular Targets and Therapeutics

Yanyan Zhu
Yike Gao
Xiaoqing Huang
Bowang Chen
Xinyi Wang
Ying Wu
Jian Sun
Xiaoyun Huang

Frontiers in Oncology

doi 10.3389/fonc.2025.1543419

515 views

Review

Published on 13 May 2025

Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment

in Cancer Molecular Targets and Therapeutics

Maryamosadat Mavaei
Simin Farokhi
Mohammad Hasan Yousefi
Arshia Fakouri
Alireza Shadab
Mohammad Hossein Abdolmohammadi
Faranak Fallahian
Hamed Afkhami

Frontiers in Oncology

doi 10.3389/fonc.2025.1533065

474 views

Original Research

Accepted on 12 May 2025

Comprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune infiltration, and prognosis

in Cancer Molecular Targets and Therapeutics

Ming Liu
Guixin Ding
Gonglin Tang
Shangjing Liu
Qiancheng Mao
Xidong Wang
Qingsong Zou
Jitao Wu

Frontiers in Oncology

doi 10.3389/fonc.2025.1547067

134 views

Original Research

Published on 12 May 2025

RACGAP1 and MKI67 are potential prognostic biomarker in hepatocellular carcinoma caused by HBV/HCV via lactylation

in Cancer Molecular Targets and Therapeutics

Muhammad Muddasar Saeed
Xinying Ma
Xinyu Fu
Ikram Ullah
Tanveer Ali
Changchuan Bai
Ying Liu
Chengyong Dong
Xiaonan Cui

Frontiers in Oncology

doi 10.3389/fonc.2025.1537084

460 views

Original Research

Accepted on 09 May 2025

Deciphering the Circadian Rhythm in Colorectal Cancer: A Bibliometric Analysis of Research Landscape and Trends

in Cancer Molecular Targets and Therapeutics

Linzi Chen
Jinhui Liu
Yuhan Tao
Ningkun Xiao

Frontiers in Oncology

doi 10.3389/fonc.2025.1591257

Original Research

Published on 09 May 2025

Single-cell and spatial transcriptomics reveal correlation between RNA methylation-related miRNA risk model and immune infiltration in hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Rong Su
Yong Du
Pan Tian
Weifang Ma
Yongfeng Hui
Shaoqi Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1553239

563 views

Case Report

Published on 09 May 2025

Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Yanqing Pan
Lingxin Yan
Shaoxi Wang
Huiling Li
Quanfang Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1530142

507 views

Original Research

Published on 09 May 2025

Uncovering key regulatory pathways and prognostic biomarkers in the tumor microenvironment of high-grade serous ovarian cancer through single-cell RNA sequencing and experimental validation

in Cancer Molecular Targets and Therapeutics

Yue Li
Long Zhao
Ying Tian
Qianqian Zhou
Xia Liu
Shucai Yang
Jinfeng Xu
Chang Zou
Jinling Zhang
Hui Luo

Frontiers in Oncology

doi 10.3389/fonc.2025.1591430

460 views

Original Research

Accepted on 08 May 2025

Multidimensional analysis suggests that ZNF433 is a promising biomarker for the diagnosis and prognosis of human cancers

in Cancer Molecular Targets and Therapeutics

Lingyu Xie
Xin Zeng
Hui Luo
Bin Xie
Xuefeng Wang
Nan Wu
Junrong Zou
Guoxi Zhang
Xiaofeng Zou
Hui Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1584042

Review

Accepted on 08 May 2025

Research Progress on NUSAP1 and Its Role in Digestive System Neoplasms

in Cancer Molecular Targets and Therapeutics

Shangui Fu
Yuting Zhuo
Tao Yu

Frontiers in Oncology

doi 10.3389/fonc.2025.1582361